1. Home
  2. Team
  3. Kevin Cheng

Kevin joined MVM in 2016. Prior to MVM, he worked across the life science and healthcare sector as a consultant at Bain & Company. Kevin completed a BA in Natural Sciences and a PhD in Oncology at the University of Cambridge, where he conducted translational research in the field of neural development.

Kevin is a member of the board of Ossio and BioProtect, and previously represented MVM on the boards of Zipline Medical and Paragon 28

Latest news

Hologic agrees to acquire Gynesonics
October 14, 2024
eXmoor Pharma Partners with Quell Therapeutics to Develop CAR-Treg Cell Therapies
September 24, 2024
Stryker agrees to acquire Vertos Medical
August 22, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
August 20, 2024
Providence Medical Technology, Inc. Announces FDA Clearance of CORUS™ Navigation Access System for Use with Medtronic’s StealthStation™ Surgical Navigation in Posterior Spinal Fusion
June 13, 2024
Nalu PNS System achieves significant and durable pain reduction, meeting the primary endpoint of the COMFORT RCT study
June 4, 2024
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
April 15, 2024
Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
GT Medical Technologies Names Per Langoe As CEO
February 20, 2024
MVM invests in icotec
January 24, 2024
View all